0001104659-19-064785.txt : 20191115 0001104659-19-064785.hdr.sgml : 20191115 20191115170131 ACCESSION NUMBER: 0001104659-19-064785 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20191115 DATE AS OF CHANGE: 20191115 EFFECTIVENESS DATE: 20191115 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Protalix BioTherapeutics, Inc. CENTRAL INDEX KEY: 0001006281 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 650643773 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-33357 FILM NUMBER: 191225232 BUSINESS ADDRESS: STREET 1: 2 SNUNIT ST STREET 2: SCIENCE PARK, POB 455 CITY: CARMIEL STATE: L3 ZIP: 20100 BUSINESS PHONE: 972-4-988-9488 MAIL ADDRESS: STREET 1: 2 SNUNIT ST STREET 2: SCIENCE PARK, POB 455 CITY: CARMIEL STATE: L3 ZIP: 20100 FORMER COMPANY: FORMER CONFORMED NAME: ORTHODONTIX INC DATE OF NAME CHANGE: 19980422 FORMER COMPANY: FORMER CONFORMED NAME: EMBASSY ACQUISITION CORP DATE OF NAME CHANGE: 19960124 DEFA14A 1 tm1922907d2_defa14a.htm DEFA14A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrant ¨

Filed by a Party other than the Registrant ¨

Check the appropriate box:

¨	Preliminary Proxy Statement

¨	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

¨	Definitive Proxy Statement

x	Definitive Additional Materials

¨	Soliciting Material Pursuant to §240.14a-12

Protalix BioTherapeutics, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

¨	No fee required.

¨	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

	1)	Title of each class of securities to which transaction applies:
	2)	Aggregate number of securities to which transaction applies:
	3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set
		forth the amount on which the filing fee is calculated and state how it was determined):
	4)	Proposed maximum aggregate value of transaction:
	5)	Total fee paid:

¨	Fee paid previously with preliminary materials.

¨	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing:

	1)	Amount Previously Paid:
	2)	Form, Schedule or Registration Statement No:
	3)	Filing Party:
	4)	Date Filed:

200 Broadacres Drive, 3rd Floor

Bloomfield, NJ 07003

P: 973.873.7700

F: 973.338.1430

www.allianceadvisors.com

November 14th, 2019

Urgent

Re: Your Investment in Protalix Biotherapeutics Inc.

Dear Stockholder,

By now you should have received your proxy materials regarding your investment with Protalix BioTherapeutics and the upcoming Special Meeting of Stockholders which is scheduled to be held on December 9, 2019.

As of the date of this letter our records indicate your vote has not yet been received.

In order to have your shares represented at the upcoming meeting you can call toll-free now at 833-785-6488 and speak with a live agent who will be able to assist you.

Please note you will need your unique control number which is located on the enclosed proxy card.

Alliance Advisors has been retained by Protalix Biotherapeutics to contact you regarding this matter.

Sincerely,

Melissa Carlson

Vice President

The Shareholder Communication Strategists

GRAPHIC 2 image_002.jpg GRAPHIC begin 644 image_002.jpg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end GRAPHIC 3 image_001.jpg GRAPHIC begin 644 image_001.jpg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